|
|assets = |equity = |num_employees = |subsid = |footnotes = financial information〔 |homepage = }} Esperion Therapeutics, Inc. is a public, American pharmaceutical company focused on the development of LDL-C-lowering therapeutics with potential for treatment of hypercholesterolemia and other cardiometabolic conditions.〔 The company is headquartered in Plymouth, Michigan.〔 == History == Esperion was founded with venture capital financing in May 1998 by four Parke-Davis colleagues who left to form the company: Roger Newton (who took the role of CEO), Tom Rea, Michael Pape and Charlie Bisgaier. The company's first Chairman was David Scheer.〔 In year 2000, the company had been listed on NASDAQ (Ticker symbol: ESPR). Pfizer acquired Esperion in December 2003 for as a defensive move to prevent ETC-216 from falling into competitors' hands.〔 Four years later, in 2007, Pfizer decided to kill the Esperion organization and development of ETC-216, but by May 2008, Roger Newton had raised sufficient capital to acquire rights to the therapeutic and Esperion from Pfizer, thereby leading to a second independent period for the company.〔 In June 2013, Esperion became a public company again through an initial public offering. , Esperion was traded on NASDAQ under the symbol "ESPR".〔(【引用サイトリンク】title=ESPR stock quote )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Esperion Therapeutics」の詳細全文を読む スポンサード リンク
|